Literature DB >> 16826217

Dichotomies in cancer research: some suggestions for a new synthesis.

Michael B Sporn1.   

Abstract

Continuing high cancer incidence and mortality raise concern about the prevailing overall approach to the control of this disease. The purpose of this article is to elaborate on fundamental dichotomies between traditional and revisionist viewpoints and then to attempt a synthesis of these contrasting perspectives. Topics considered include the importance of controlling carcinogenesis in its earliest stages; consideration of epigenetic, as well as genetic, factors in cancer; development of appropriate genetic animal models of carcinogenesis; the need for multifunctional agents to prevent and treat cancer; and the limits of reductionism. The need for development of new preventive and therapeutic measures that will maintain quality of life, not merely extend life, is stressed. Finally, the importance of context in cancer biology is emphasized, as epitomized in Walt Whitman's famous quotation that "Nothing out of its place is good and nothing in its place is bad."

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826217     DOI: 10.1038/ncponc0536

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  8 in total

1.  Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.

Authors:  Karen T Liby
Journal:  Dose Response       Date:  2013-08-01       Impact factor: 2.658

2.  Perspective: The big C - for Chemoprevention.

Authors:  Michael B Sporn
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

3.  Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.

Authors:  James J Liu; Rulong Shen; Li Chen; Yin Ye; Gang He; Keding Hua; David Jarjoura; Toru Nakano; Ganju K Ramesh; Charles L Shapiro; Sanford H Barsky; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

4.  Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.

Authors:  Karen T Liby; Darlene B Royce; Renee Risingsong; Charlotte R Williams; Anirban Maitra; Ralph H Hruban; Michael B Sporn
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-19

5.  Cancer as robust intrinsic state of endogenous molecular-cellular network shaped by evolution.

Authors:  Ping Ao; David Galas; Leroy Hood; Xiaomei Zhu
Journal:  Med Hypotheses       Date:  2007-09-04       Impact factor: 1.538

6.  Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.

Authors:  Karen Liby; Renee Risingsong; Darlene B Royce; Charlotte R Williams; Tian Ma; Mark M Yore; Michael B Sporn
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

Review 7.  Targeting the tumor microenvironment.

Authors:  Paraic A Kenny; Genee Y Lee; Mina J Bissell
Journal:  Front Biosci       Date:  2007-05-01

8.  Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Authors:  Karen Liby; Renee Risingsong; Darlene B Royce; Charlotte R Williams; Mark M Yore; Tadashi Honda; Gordon W Gribble; William W Lamph; Nicola Vannini; Ilaria Sogno; Adriana Albini; Michael B Sporn
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.